Human Papillomavirus (HPV) infection is considered as the most common sexually transmitted virus infection (
1). Cervical cancer is the second/third leading cause of cancer in females, with an estimated 493,000 cases and 273,000 deaths, annually (
2). The Human Papillomavirus genotypes 6, 11, 16 and 18 are transmitted sexually and considered as the most common cause of anogenital warts and cervical cancers (
3,
4). Human Papillomavirus are small, non-enveloped, double-stranded circular DNA, 8 kb in size, surrounded by a 55-nm capsid. So far, more than 150 genotypes of the virus have been identified (
5). Furthermore, HPV are generally divided to groups of low and high risk. Low risk HPVs result in benign tumors, while high-risk HPVs generate malignant tumors. Human Papillomavirus types 6 and 11 have low malignant potential; however, some studies have introduced these types as risk factors for vulvar malignancy (
1,
2). Genotypes 16 and 18 of HPV are high risk HPVs and responsible for 70% of all cervical cancer cases (
3-
5). A high prevalence of HPV genotypes 16 and 53 has been reported in Iran (
6,
7).
The Pap smear, cytological evaluations, serological and immunohistochemical staining methods for identification of HPV variants are insensitive. On the other hand, a highly specific and sensitive test for HPV genotyping determination is the polymerase chain reaction (PCR) (
3). Thus, the PCR can be a screening test for detection of HPV DNA in precancerous lesions of genital warts (
4,
5).